Akhil Ravi Appointed CEO of Aurigene Pharmaceutical Services Ltd


Dr. Reddy's Laboratories Ltd. along with its subsidiaries together referred to as "Dr. Reddy's") today announced that it named Akhil Ravi as CEO for its wholly-owned subsidiary Aurigene Pharmaceutical Services Ltd. (APSL) effective February 1, 2022.

Since joining Dr. Reddy's in 2018 from McKinsey & Company, Akhil Ravi has served as Head of Strategy for Services and Active Pharmaceutical Ingredients (APIs), and headed the Sales of APIs in Europe. In addition, he has also had a brief stint as Plant Head. Akhil holds a BTech degree in Chemical Engineering from IIT Bombay and an MBA from the Indian School of Business (ISB).

"Akhil is very well prepared for this role. He was instrumental in growing our API business through product development and an improved service experience for our B2B customers through digital platforms. His strong background in customer service, sales, strategy, and management make him an ideal leader for Aurigene, and we look forward to his accomplishments in this new role." said Deepak Sapra, CEO of API and Services at Dr. Reddy’s and Member of the Board at Aurigene.

Akhil Ravi said: "Aurigene Pharmaceutical Services is a dynamic partner for global pharma companies. With its integrated services from clinical research up to commercial manufacturing for small and large molecules, it is able to significantly speed up the journey of an NCE/NBE (New Chemical and Biological Entities) to the patient. I am very thrilled to join Aurigene and work with the team to serve innovative global pharma and biotech companies."


About Aurigene Pharmaceutical Services Ltd. (APSL): Aurigene Pharmaceutical Services Limited (APSL) is an integrated partner for global pharma companies. It covers the entire value chain for new therapeutics, from drug discovery, clinical research, and development to manufacturing APIs and formulation at commercial scales. It has development laboratories from discovery to clinical phase III for New Chemical and Biological Entities (NCEs/NBEs) and cGMP manufacturing facilities in the UK, Mexico, USA, and India.

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

SOURCE: Dr. Reddy's

Related Videos
© 2024 MJH Life Sciences

All rights reserved.